These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21214493)

  • 1. Different toxicity profiles for drug- versus radionuclide-conjugated BR96 monoclonal antibodies in a syngeneic rat colon carcinoma model.
    Nilsson R; Eriksson SE; Sjögren HO; Tennvall J
    Acta Oncol; 2011 Jun; 50(5):711-8. PubMed ID: 21214493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity-reducing potential of extracorporeal affinity adsorption treatment in combination with the auristatin-conjugated monoclonal antibody BR96 in a syngeneic rat tumor model.
    Nilsson R; Mårtensson L; Eriksson SE; Sjögren HO; Tennvall J
    Cancer; 2010 Feb; 116(4 Suppl):1033-42. PubMed ID: 20127954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model.
    Eriksson SE; Ohlsson T; Nilsson R; Tennvall J
    Cancer Biother Radiopharm; 2012 Mar; 27(2):134-40. PubMed ID: 22229635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
    Sjögren HO; Isaksson M; Willner D; Hellström I; Hellström KE; Trail PA
    Cancer Res; 1997 Oct; 57(20):4530-6. PubMed ID: 9377565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.
    Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
    Cancer; 2010 Feb; 116(4 Suppl):1043-52. PubMed ID: 20127949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential radioimmunotherapy with 177Lu- and 211At-labeled monoclonal antibody BR96 in a syngeneic rat colon carcinoma model.
    Eriksson SE; Elgström E; Bäck T; Ohlsson T; Jensen H; Nilsson R; Lindegren S; Tennvall J
    Cancer Biother Radiopharm; 2014 Aug; 29(6):238-46. PubMed ID: 24971673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with unlabeled mAb BR96 after radioimmunotherapy with 177Lu-DOTA-BR96 in a syngeneic rat colon carcinoma model.
    Eriksson SE; Ohlsson T; Nilsson R; Tennvall J
    Cancer Biother Radiopharm; 2012 Apr; 27(3):175-82. PubMed ID: 22417248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The intratumoral distribution of radiolabeled 177Lu-BR96 monoclonal antibodies changes in relation to tumor histology over time in a syngeneic rat colon carcinoma model.
    Örbom A; Eriksson SE; Elgström E; Ohlsson T; Nilsson R; Tennvall J; Strand SE
    J Nucl Med; 2013 Aug; 54(8):1404-10. PubMed ID: 23804328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracorporeal whole-blood immunoadsorption enhances radioimmunotargeting of iodine-125-labeled BR96-biotin monoclonal antibody.
    Garkavij M; Tennvall J; Strand SE; Sjögren HO; JianQing C; Nilsson R; Isaksson M
    J Nucl Med; 1997 Jun; 38(6):895-901. PubMed ID: 9189138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of intravenous Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma.
    Mulligan T; Carrasquillo JA; Chung Y; Milenic DE; Schlom J; Feuerstein I; Paik C; Perentesis P; Reynolds J; Curt G
    Clin Cancer Res; 1995 Dec; 1(12):1447-54. PubMed ID: 9815943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy.
    Mårtensson L; Wang Z; Nilsson R; Ohlsson T; Senter P; Sjögren HO; Strand SE; Tennvall J
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7104s-7108s. PubMed ID: 16203809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
    Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R
    Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody.
    Bloechl S; Beck R; Seidl C; Morgenstern A; Schwaiger M; Senekowitsch-Schmidtke R
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7070s-7074s. PubMed ID: 16203804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
    Behr TM; Memtsoudis S; Vougioukas V; Liersch T; Gratz S; Schmidt F; Lorf T; Post S; Wörmann B; Hiddemann W; Ringe B; Becker W
    Anticancer Res; 1999; 19(4A):2427-32. PubMed ID: 10470170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 125I- and (111)In-labeled monoclonal antibody BR96 for tumor targeting in combination with extracorporeal immunoadsorption.
    Garkavij M; Tennvall J; Ohlsson T; Lindgren L; Hindorf C; Sjögren HO; Strand SE
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3059s-3064s. PubMed ID: 10541344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
    Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
    Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin.
    Trail PA; Willner D; Bianchi AB; Henderson AJ; TrailSmith MD; Girit E; Lasch S; Hellström I; Hellström KE
    Clin Cancer Res; 1999 Nov; 5(11):3632-8. PubMed ID: 10589780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
    Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.